Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04200378 · ClinicalTrials.gov registry record

Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair

A clinical trial, sponsored by Mayo Clinic.

Completed
Registry status
22
Enrollment target

NCT04200378: Completed study, sponsored by Mayo Clinic.

NCT04200378 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04200378 has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
22 participants
Enrollment target

Study Summary

Studying the effects of Trans-catheter Mitral Valve Repair (TMVr) on the hemodynamics and biomarkers in patients with severe mitral valve regurgitation.

Primary Outcome

Change in stroke volume index 10 minutes post repair to baseline stroke volume index measurement (L/m\^2)

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2020-08-20
Est. Completion 2024-04-11
Mayo Clinic

2,844 total trials

What the finished NCT04200378 record still lists

NCT04200378 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT04200378 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04200378 about?

NCT04200378 is a clinical study titled "Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair". Studying the effects of Trans-catheter Mitral Valve Repair (TMVr) on the hemodynamics and biomarkers in patients with severe mitral valve regurgitation.

What is the current status of trial NCT04200378?

This trial is currently completed. The enrollment target is 22 participants. The study started on 2020-08-20. Estimated completion is 2024-04-11.

Who is sponsoring clinical trial NCT04200378?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04200378, the US trial registry maintained by the National Library of Medicine. NCT04200378 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.